CR20250179A - Solución líquida de buen sabor con alta concentración de miglustat - Google Patents

Solución líquida de buen sabor con alta concentración de miglustat

Info

Publication number
CR20250179A
CR20250179A CR20250179A CR20250179A CR20250179A CR 20250179 A CR20250179 A CR 20250179A CR 20250179 A CR20250179 A CR 20250179A CR 20250179 A CR20250179 A CR 20250179A CR 20250179 A CR20250179 A CR 20250179A
Authority
CR
Costa Rica
Prior art keywords
miglustat
solution containing
high concentration
liquid solution
containing high
Prior art date
Application number
CR20250179A
Other languages
English (en)
Inventor
Adeline Duchêne
Mathieu Charveriat
Julien Veys
Melanie Anagonou
Original Assignee
Theranexus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theranexus filed Critical Theranexus
Publication of CR20250179A publication Critical patent/CR20250179A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Seasonings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una formulación estable y agradable al paladar que contiene una alta cantidad de miglustat, especialmente indicada para niños o personas con dificultad para tragar. Esta formulación altamente concentrada contiene al menos 150 mg/mL de miglustat y, como excipientes, benzoato de sodio, ácido tartárico, un edulcorante y, opcionalmente, un aroma ácido. Esta formulación puede administrarse ventajosamente junto con activadores terapéuticos de la enzima disacaridasa para aliviar los efectos secundarios intestinales del miglustat.
CR20250179A 2022-10-07 2023-10-09 Solución líquida de buen sabor con alta concentración de miglustat CR20250179A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22306512.9A EP4349334B1 (en) 2022-10-07 2022-10-07 Palatable liquid solution containing high concentration of miglustat
PCT/EP2023/077910 WO2024074723A1 (en) 2022-10-07 2023-10-09 Palatable liquid solution containing high concentration of miglustat

Publications (1)

Publication Number Publication Date
CR20250179A true CR20250179A (es) 2025-09-04

Family

ID=83903187

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250179A CR20250179A (es) 2022-10-07 2023-10-09 Solución líquida de buen sabor con alta concentración de miglustat

Country Status (15)

Country Link
EP (2) EP4349334B1 (es)
CN (1) CN120390639A (es)
AU (1) AU2023357503A1 (es)
CL (1) CL2025001013A1 (es)
CO (1) CO2025005057A2 (es)
CR (1) CR20250179A (es)
DO (1) DOP2025000082A (es)
ES (1) ES3031740T3 (es)
HR (1) HRP20250679T1 (es)
HU (1) HUE071860T2 (es)
MX (1) MX2025004114A (es)
PE (1) PE20251532A1 (es)
PL (1) PL4349334T3 (es)
SM (1) SMT202500225T1 (es)
WO (1) WO2024074723A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
ES2779006T3 (es) 2013-01-09 2020-08-13 Amicus Therapeutics Inc Composiciones de DNJ parenterales estables
EP3944858A1 (en) * 2020-07-30 2022-02-02 Beyond Batten Disease Foundation Combination product containing trehalose and miglustat for treating lysosomal diseases

Also Published As

Publication number Publication date
PE20251532A1 (es) 2025-06-05
EP4598529A1 (en) 2025-08-13
EP4349334A1 (en) 2024-04-10
SMT202500225T1 (it) 2025-07-22
WO2024074723A1 (en) 2024-04-11
AU2023357503A1 (en) 2025-04-24
CN120390639A (zh) 2025-07-29
HUE071860T2 (hu) 2025-09-28
DOP2025000082A (es) 2025-07-31
ES3031740T3 (en) 2025-07-10
MX2025004114A (es) 2025-09-02
CL2025001013A1 (es) 2025-08-08
EP4349334B1 (en) 2025-03-19
EP4349334C0 (en) 2025-03-19
PL4349334T3 (pl) 2025-07-14
CO2025005057A2 (es) 2025-07-28
HRP20250679T1 (hr) 2025-08-01

Similar Documents

Publication Publication Date Title
US10342822B2 (en) Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system
ES2382993T3 (es) Composición líquida de acetato de calcio
CN1302183A (zh) 用于治疗上呼吸道病症的木糖醇组合物
JPS63313726A (ja) 神経細胞に影響を与えることにより偏頭痛のような神経性疾患を処理する方法および組成物
US11654127B2 (en) Composition for use in the prevention and/or treatment of Oncologic Treatment Induced Orogastrointestinal Mucositis
US11844811B2 (en) Methods and compositions for alleviating respiratory dysfunction
AU782564B2 (en) Treatment of fibromyalgia with Ubiquinone 10 and succinic acid
De Conno et al. Oral complications in patients with advanced cancer
US5712259A (en) NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
EP2799074A1 (en) Iron bis-glycinate chelate for use in the oral treatment of anemia in patients with celiac disease
TW200306804A (en) Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
US7649017B2 (en) Compositions intended for the treatment of peripheral neuropathies, preparation thereof and uses of same
US20070264370A1 (en) Composition and methods for the treatment of joint pain using Angelica gigas Nakai extract and powder as combined with Glucosamine Sulfate, or Chondroitin Sulfate and HCL, or MSM, or aspirin, or Celedrin, and as combinations thereof in powder, pill, capsule, spray, liquid, and gelcap form
MX2025004114A (es) Solucion liquida de buen sabor con alta concentracion de miglustat
ES2618930T5 (es) Composición que comprende diaminooxidasa para la prevención de los síntomas de la resaca
Davies Salivary gland dysfunction
US20210023126A1 (en) Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system
Storey The role of oral glutamine in pediatric bone marrow transplant
US20060263385A1 (en) Composition to relieve side effects of alcohol intoxication
CN111000871A (zh) 一种口腔喷剂及其制备方法
BR0008442B1 (pt) Composição farmacêutica na forma de formulação efervescente, contendo metamizol
US20060280695A1 (en) Methods and compositions for the prevention, suppression and elimination of oral pain
Manappallil et al. Hypokalemia myopathy due to Piperacillin-tazobactam induced resistant hypokalemia
RU2572705C1 (ru) Композиция для полоскания полости рта
EA052752B1 (ru) Композиция зубной пасты, направленная на улучшение гигиены полости рта и улучшение эректильной функции